EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study

Kilian Eyerich iD, Melinda J Gooderham, Juan Francisco Silvestre, Stephen P Shumack, Pedro Mendes-Bastos iD, Valeria Aoki iD, Michela Ortoncelli, Jonathan I Silverberg iD, Henrique D Teixeira, Shirley H Chen, Brian M Calimlim iD, Shunya Takemoto iD und 3 weitere

Journal of the European Academy of Dermatology and Venereology · 2024-02 · 38 (2) · 340-353

DOI: 10.1111/jdv.19500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 25.09.2023. Verfasst von Kilian Eyerich und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD), a relapsing, inflammatory skin disease, is associated with pruritus that can negatively affect patients' quality of life. Understanding the burden of AD is critical for informing and tailoring treatment and disease management to improve patient outcomes. This study characterized global treatment patterns and the clinical, psychosocial and economic burden of moderate‐to‐severe AD.

Methods

MEASURE‐AD was a cross‐sectional 28‐country study in patients with physician‐confirmed moderate‐to‐severe AD who were either receiving or eligible for systemic therapy for AD. Patients ≥12 years were enrolled between December 2019 and December 2020 while attending routine office or clinic visit. Primary outcomes included Worst Pruritus Numeric Rating Scale (WP‐NRS; range: 0–10) and Dermatology Life Quality Index (DLQI; range: 0–30) and Children's DLQI (CDLQI; range: 0–30). Secondary outcomes included physician‐ and patient‐reported clinical, psychosocial and economic burden.

Results

Of the 1591 patients enrolled, 1558 (1434 adults and 124 adolescents) fulfilled all patient selection criteria and were included in this analysis. Almost all patients (98.4%) in the total population were using AD medications and more than half (56%) were receiving systemic medication (15% systemic monotherapy). The most used systemic therapies were dupilumab (56.3%), systemic glucocorticoids (18.1%) and methotrexate (16.2%). Mean WP‐NRS was 5.3 in the total population, and most patients (≥55%) reported moderate‐to‐severe pruritus (WP‐NRS ≥4). Mean DLQI was 10.8 and mean CDLQI was 9.6. Secondary endpoints demonstrated substantial clinical, psychosocial, and economic burden of disease. Subgroup analysis demonstrated that patients receiving systemic therapy had lower disease burden than those not taking systemic medications.

Conclusions

While systemic therapy lowers overall disease burden, patients with moderate‐to‐severe AD continue to have substantial multidimensional disease burden and uncontrolled disease. Overall, there is a need for effective disease management, including effective treatments that improve patients' psychosocial outcomes and reduce the economic burden of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAdultChildAdolescentHumansQuality of LifeCross-Sectional StudiesFinancial StressPatient Reported Outcome MeasuresNeoplasm Recurrence, LocalPruritusTreatment OutcomeSeverity of Illness Index

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.
  • SKiN Centre for Dermatology, Peterborough, Ontario, Canada.
  • Queen's University, Kingston, Ontario, Canada.
  • Probity Medical Research Inc, Waterloo, Ontario, Canada.
  • Department of Dermatology, Hospital General de Alicante, Alicante, Spain.
  • Department of Dermatology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Kilian Eyerich, Pedro Mendes-Bastos, Valeria Aoki, Jonathan I Silverberg, Brian M Calimlim, Shunya Takemoto, Alan D Irvine

Förderung

  • AbbVie

Zitieren

APA

Eyerich, K., Gooderham, M. J., Silvestre, J. F., Shumack, S. P., Mendes-Bastos, P., Aoki, V., Ortoncelli, M., Silverberg, J. I., Teixeira, H. D., Chen, S. H., Calimlim, B. M., Takemoto, S., Sancho, C., Fritz, B., & Irvine, A. D. (2024). Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study. Journal of the European Academy of Dermatology and Venereology, 38(2), 340-353. https://doi.org/10.1111/jdv.19500

Vancouver

Eyerich K, Gooderham MJ, Silvestre JF, Shumack SP, Mendes-Bastos P, Aoki V, et al. Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study. Journal of the European Academy of Dermatology and Venereology. 2024;38(2):340-353. doi:10.1111/jdv.19500

BibTeX
@article{Eyerich2024,
  author = {Eyerich, Kilian and Gooderham, Melinda J and Silvestre, Juan Francisco and Shumack, Stephen P and Mendes-Bastos, Pedro and Aoki, Valeria and Ortoncelli, Michela and Silverberg, Jonathan I and Teixeira, Henrique D and Chen, Shirley H and Calimlim, Brian M and Takemoto, Shunya and Sancho, Cristina and Fritz, Björn and Irvine, Alan D},
  title = {Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  volume = {38},
  number = {2},
  pages = {340--353},
  doi = {10.1111/jdv.19500}
}
Kostenlos starten →